Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of “Buy” from Analysts

Insmed, Inc. (NASDAQ:INSM) has received a consensus rating of “Buy” from the twenty-four brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twenty have given a buy rating and three have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $212.6667.

Several research firms have recently weighed in on INSM. Roth Mkm upgraded Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $166.00 to $212.00 in a research report on Monday. The Goldman Sachs Group increased their price objective on Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Citigroup reaffirmed an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Finally, Guggenheim dropped their target price on shares of Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a report on Thursday, December 18th.

Insmed Stock Up 0.8%

INSM opened at $164.86 on Thursday. The company has a market cap of $35.54 billion, a PE ratio of -25.72 and a beta of 1.10. Insmed has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a 50-day moving average price of $150.14 and a 200 day moving average price of $166.41. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. The company’s quarterly revenue was up 152.6% on a year-over-year basis. Sell-side analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 19,215 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00. Following the transaction, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at $51,864,579. This trade represents a 5.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the transaction, the insider owned 41,754 shares in the company, valued at approximately $7,315,300.80. This represents a 67.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 189,651 shares of company stock worth $31,533,654 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insmed

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new position in Insmed during the fourth quarter worth approximately $506,625,000. Vanguard Group Inc. grew its holdings in Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after buying an additional 2,291,328 shares in the last quarter. RTW Investments LP increased its stake in shares of Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after acquiring an additional 1,758,321 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares during the last quarter. Finally, Orbis Allan Gray Ltd purchased a new position in shares of Insmed during the 2nd quarter worth $153,389,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.